Incyte Corp
tafasiamab
diffuse large B-cell lymphoma
Resolved
157days ago
Phase 3 readout · ~ Jan 31, 2026 estimated
What's at stake
Phase 3 trial results for tafasiamab in diffuse large B-cell lymphoma are due ~ Jan 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 16h ago
“In January 2026, the Company announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating tafasitamab and lenalidomide in addition to R-CHOP as a first-line treatment for newly diagnosed diffuse large B-cell lympho”